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ABSTRACT 
 
This thesis describes work towards the total synthesis of a 7-aza analogue of the 
Amaryllidaceae alkaloid narciclasine, a potent anticancer compound which suffers from 
a poor solubility profile. A key strategy in the formation of the C-ring is the 
biotransformation of bromobenzene by E.coli JM109. The densely substituted 
heterocyclic A-ring is obtained by sequential directed ortho-metalation and the 
fragment union accomplished with an amide coupling and subsequent intramolecular 
Heck reaction.  
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1. Introduction 
The plants from the Amaryllidaceae family have long been under scrutiny for the 
medicinal properties of their extracts. The present scientific evidence shows that the 
isocarbostyril constituents of the Amaryllidaceae family, particularly narciclasine 1 and 
pancratistatin 2, and their congeners are the metabolites that are most responsible for 
the therapeutic benefits in the treatment of cancer. However, these compounds have 
issues inhibiting their development into drug candidates, such as poor solubility in 
water, densely functionalised structure, low natural abundance, and an unknown 
mechanism of action.  
Narciclasine 1 was isolated and discovered by Ceriotti1 in 1968 and pancratistatin 
2 by Pettit2 in 1984 (Figure 1), these two compounds were found to have antineoplastic 
activity when they were screened for possible drugs. Unfortunately, although these 
compounds were potent, solubility is a problem. Chemists attempted to discover 
possible analogues that will not only solve the issue of solubility but also further 
increase the biological activity. 
 
 
Figure 1- Structure of Narciclasine and Pancratistatin  
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 The main objective of this project is to construct the A-ring aza-analogues of 
narciclasine that have the same or greater biological activity and to solve the solubility 
issues that have been found with this family (Figure 2). A key principle of the Hudlický 
group approach to synthesis is that the process should be efficient, elegant, and 
environmentally benign. The rapid construction of the desired functionality and the 
assembly of the fragments to yield the target compound exemplify these principles, with 
the synthesis having a convergent approach that begins with a ‘green’ starting material. 
The goal of this research project is to produce various structural analogs for the 
investigation of structure-activity relationship (SAR) studies in order to determine 
whether analogues possess comparable or increased anticancer activity. In order to be a 
drug candidate it has to exhibit improved water solubility, and our approach to this 
problem is the introduction of a nitrogen atom, which we propose will enhance the 
polarity and hence hydrophilicity of the compounds. 
 
Figure 2- General Strategy for the synthesis of A-ring hetero-analogues of Narciclasine 
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2. Historical 
2.1. Amaryllidaceae Alkaloids 
2.1.1. Discovery and Biosynthesis 
The anticancer properties of Amaryllidaceae extracts were discovered by 
Hippocrates of Kos, also known as Father of Medicine, from the oil of Narcissus poeticus 
L. The oil was used for the treatment of uterine cancer. His successors, Pedanius 
Dioscorides and Soranus of Ephesus, continued using these treatments for many years.3 
There are specific metabolites that are responsible for these anticancer properties. The 
first modern in-depth study began with the isolation of lycorine 10 from N. 
pseudonarcissus in 1877 (Figure 3).4 The main focus of this section will be on 
components possessing the isocarbostyril structural motif 11. 
 
 
 
Figure 3- The Structure of Lycorine and isocarbostyril moiety 
 
In the 20th century, the alkaloids that possessed the highest anticancer activity 
were isolated and found to contain an isocarbostyril moeity. Narciclasine 1 was 
discovered in 1968,1 which was closely followed by 7-deoxynarciclasine (lycoricidine, 
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12).5 Twenty years later, Pettit2  discovered pancratitastin 2 in 1984, and Ghosal6 
isolated 7-deoxypancratistatin 13. In 1975, a semi-synthetic route to trans-
dihydronarciclasine 14 was published,7 but was isolated from natural source in 1990 by 
Pettit.8 The last isolation of the narciclasine species was 7-deoxy-trans-
dihydronarciclasine 15 in 1993 by Pettit.9 
 
 
Figure 4- Three major isocarbotyril congeners and 7-deoxy versions  
 
 The biosynthesis of the Amaryllidaceae alkaloids has been investigated and 
described extensively in Kornienko’s 2008 review.3 The pivotal intermediate in the 
biosynthesis, O-methylnorbelladine (16, Figure 5) is derived from amino acids 
phenylalanine 17 and tyrosine 18. Through a series of biotransformations, the derived 
amino acids procatechuic aldehyde 19 and tyramine 20 condense to afford Shiff base 21. 
The reduction of 21 yields norbelladine 22 and in turn is methylated to O-
methylnorbelladine 16. There are two types of coupling pathways in this class of 
alkaloids, para-ortho oxidative or para-para. Radioactive labeling studies concluded that 
narciclasine 1 follows a para-para phenol oxidative pathway.10 Oxidation of the O-
5 
 
methylnorbelladine and subsequent aza- Michael addition the noroxomaritidine 23 is 
formed, after a series of oxidation steps of the alkaloid narciclasine 1 is produced. 
 
 
Figure 5- The Biosynthetic Route to Narciclasine  
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2.1.2. Selected Total Syntheses of Narciclasine  
Although narciclasine 1 was isolated in 1968, it was not successfully synthesized until 
1997 by Rigby. This section will not cover all total syntheses of narciclasine , but a select 
few published by Rigby,11 Keck,12 Hudlicky,13 and Yan.14  In order to follow the 
nomenclature and numbering in this document, the system is displayed in Figure 6.  
 
Figure 6- Narciclasine and Pancratistatin nomenclature and numbering system 
 
 The first enantioselective synthesis of narciclasine was done by Rigby11 in 1997 
(Scheme 1). The preparation of the syn-epoxy alcohol 27 began by transforming the 
methyl ester 24 by Berchtold conditons.15 The A-ring fragment 29 was prepared in four 
steps from 2,3-dihydroxybenzaldehyde 28. Before the cyclization of A and the C-ring, the 
hydroxyl is protected by ethoxy ethyl ether 30. In order to couple the two fragments 
together, the carboxylic acid 27 is converted to an isocyanate and methylated which led 
to the formation of amide 31. After the installation of p-methoxybenyzl group, a 
photochemical enamide cyclization was done. With the use of diphenyl diselenide, the 
epoxide is opened followed by the acylation and protection of the diol by acetonide 32. 
The removal of all protecting groups results in the first enantioselective total synthesis 
of narciclasine 1 in 27 steps.11  
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a) NBS, AlBN, PhH, reflux; b) AlBN, Bu3SnH, PhH, 75%; c) 1O2, hν, rose bengal; d) 
(Ph3P)2RuCl2, CH2Cl2; e) NaOMe, MeOH, 30%; f) n PrCOCl, NEt3; g) cholesterol esterase;  
h) TBSCl, imidazole; i) i)LiOH, MeOH, H2O, 42%; ii)  DPPA, NEt3, PhH;  j) CH2Br2, K2CO3; k) 
m-CPBA; l) KOH/EtOH; m) CF3CO2Ag, Br2, 45%; n) ethyl vinyl ether, PPTS, 70%; o) i) n-
BuLi, THF, -78 °C, 27, 52%;  p) i) PMBBr, NaH; ii) PPTS, MeOH, 76%; iii) hν, PhH, 46%; iv) 
(PhSe)2 , NaBH4; v) NaH, AcCl, 48%; q) i) OsO4, TMNO, t-BuOH; ii) TsOH, (CH3)2C(OMe)2, 
76%; r) i)TBAF, THF; ii) Burgess Reagent, 64%; iii) K2CO3, MeOH; iv) n-BuLi, THF, O2; v) 
TsOH, 37%. 
 
 
Scheme 1- Rigby’s Enantioselective Total Synthesis of Narciclasine 
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 Keck and colleagues12 did an in-depth study of which protecting group is ideal for 
the 7-hydroxyl of 1 (Scheme 2). The aldehyde 35 was converted to 36 according to the 
procedure published by Gilman,16 followed by metalation using n-BuLi with trimethyl 
borate and hydrogen peroxide is added to form the hydroxyl which is subsequently 
protected by TBS-Cl. After the second metalation and quenching by iodine, aryl iodide 
37 was obtained. During the conversion of the dimethyl amide to methyl ester TBS was 
also removed, therefore the protecting group was altered to tosylate which can possibly 
be removed during the SmI2 reduction step.  Songashira coupling of 34 with 37 afforded 
38, soon after the radical cyclization. The cyclization, reductive removal of thiophenol 
and tosylate proceeded in one step, however the reaction was slow and low yielding. 
Alternatively a stepwise approach which included deprotection, cyclization, and removal 
of thiophenol to afford 1 with the overall yield of 26% in 14 steps.  
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a) MnO2, NaCN, Me2NH, IPA, 95%; b) n-BuLi, TMEDA, -104 °C, B(OMe)3, THF c) HOAc, 
H2O2, 78%; d)TBSCl, imidazole, 95%; e) n-BuLi, TMEDA, -104 °C, Et2O, I2, 72%; f) 
Me3OBF4, Na2HPO4, MeCN, 91%; g) MeI, K2CO3, 82%; h)TsCl, pyridine, 86%;  i) Pd(OAc)2, 
CuI, NEt3, 34, PPh3, THF, 75%; j) PhSH, hν, 27 °C, 73%; k) SmI2,THF, H2O, 0 °C, 94%; l) MeI, 
K2CO3, DMF, 96%; m) Me3Al, THF, -15-65 °C; 72%; n) SmI2, MeOH, THF, 0 °C, 2h, 87%; o) 
TFA, 0 °C, 89% 
Scheme 2- Keck’s Total Synthesis of Narciclasine 
 
 The chemoenzymatic dihydroxylation has been a long standing procedure in the 
Hudlicky’s lab (Scheme 3).13 This useful transformation was firstly described by Gibson.17 
The m-bromobenzene 41 is subjected to whole-cell fermentation with E.coli JM109 
(pDTG601A) yielding diol 42.  Subsequently 42 was converted to the bicyclic oxazine 43, 
which then reacts with 44 via Suzuki coupling to produce 45. The reduction of enone 
using NaBH4 delivered the undesired stereochemistry on carbon 2, therefore under 
10 
 
Mitsunobu conditions the correct stereochemistry was obtained to yield 47. The closure 
of ring B was done by a modification of the Bischler-Napieralski,18 all protecting groups 
were removed and 1 was obtained in 12 steps.  
 
 
 
 
a) E.coli JM109 (pDTG601A), 4g/L; b) DMP, acetone, TsOH, rt, NHCO2Me, NaIO4, rt, 70%, 
Al(Hg), THF, 80%; c) i) 44,Mo(CO)6, MeCN-H2O, reflux, 75%; ii) Pd(PPh3), aq. Na2CO3, 
PhH, reflux, 30%; d) NaBH4, CeCl3, MeOH, 0 °C , 80%; e) BzOH, Bu3P, DEAD, THF, rt, 65%; 
f) i) Dowex 50X8-100, MeOH, rt; ii) Ac2O, pyridine, DMAP, rt, 70%; g) i) Tf2O, DMAP, 
CH2Cl2, 0 °C, 40%; ii) Amberlyst A21, MeOH, rt; iii) LiCl, DMF, 120 °C, 20%.  
Scheme 3- Hudlicky’s Total Synthesis of Narciclasine 
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 a) i) 50, CH2Cl2; ii) Al(Hg), MeCN, 85%; b) i) NsCl, DBU, NEt3, MeCN; ii) TBSCl, DBU, rt, 
78%; c) NBS, acetone, H2O, 98%; d) 52, K2CO3, MeCN, 88%; e) i) SnCl4, CH2Cl2; ii) Ac2O, 
K2CO3, 98%; f) thioglicolic acid, LiOH, DMF, 78%; g) i) Boc2O, MeCN; ii) RuCl3, NaIO4, H2O, 
67%; h) DBU, benzene, 96%; j) i) HCOOH, THF; ii) LAH, THF, 65%. 
Scheme 4- Yan’s Total Synthesis of Narciclasine  
 
 The most recent synthesis of 1 was reported by Elango and Yan in 2002 (Scheme 
4).14 In order to prepare the conduramine 49, a one-pot cycloaddition of 48 and 50 was 
carried out and a reduction with Al(Hg). Protection of 49 gave conduramine 51 which 
was further reacted with NBS to produce bromohydrins, subsequently reacting with 52 
to yield the epoxide 53. Formation of ring B is mediated by Lewis acid catalyzed 
intramolecular arene coupling to yield 54. After the removal of nosyl, the compound 
12 
 
was treated with Boc2O, following the addition of RuCl3 and NaIO4 in order for the 
benzylic oxidation to occur. After heating the reaction mixture with DBU to obtain the 
10a-10b bond after a series of deprotection steps, 1 is obtained in 9 steps with an 
overall yield of 19%.  
2.1.3. Total Syntheses of Lycoricidine  
Lycoricidine 12 was isolated from the bulbs of Lycoris radiata in 1968 by 
Okamoto.5 In 1975 the first racemic total synthesis was published by Ohta,19 but it was 
not until 1982 when the first enantioselective synthesis of 12 was achieved by Paulsen 
and Stubbe (Scheme 5).20 Since this first publication, many selective and efficient 
syntheses have been developed by Ogawa,21 Hudlicky,22 Keck,12 and Yan.23  
 
 
 
13 
 
 
a) i) CH3NO2, NaOH; ii) Ac2O, TsOH, 75%; b) K2CO3, benzene, 71%; c) 56, n-BuLi, THF; d) i) 
AcOH, H2O; ii) NaHCO3, MeOH, 34%; e) H2, Pd/C, MeOH, 77%; f) K2CO3, MeOH, 72%; g) 
BzCl, pyridine, DMAP; h) SOCl2, pyridine; 70% for 2 steps; i) NH3, MeOH. 
Scheme 5- First Enantioselective Synthesis of Lycoricidine  
Paulsen and Stubbe successfully achieved an asymmetric synthesis by starting 
from glucose derivative 57, Scheme 5.20 The aldehyde 57 was transformed to the 
nitroalkene 58 using a Henry reaction, which was reacted with lithiated 56 to produce 
59.  The deprotection of the acetonide afforded the cyclized product 60, after which 
reduction and recyclization of 61 led to another one of the Amaryllidaceae alkaloids, 7-
deoxypancratistatin 13. By selective reprotection and elimination the desired product 
lycoricidine 12 was synthesized.  
 
14 
 
 
 
a) Pseudomonas putida; b) 2,2-DMP, acetone, p-TsOH; c) benzyl hydroxycarbamate, 
Bu4NIO4, CH2Cl2; 74% d) i) Al(Hg), THF, 91%; ii) ClSiMe2Pri, Imidazole, CH2C12, 98%; e) i) n-
BuLi, THF, -78 °C; ii) Br-piperonyloyl chloride, 77%; iii)Pd(OAc)2, TI(OAc), DIPHOS, anisole, 
27%; f) Pd(C), cyclohexene, EtOH, 99%; g) i) CF3CO2H, 0 °C, 85%.  
 
Scheme 6- Hudlicky’s Total Synthesis of Lycoricidine  
 Before the report of Hudlický’s 1992 (+)-Lycoricidine synthesis, there was none 
shorter than 15 steps (Scheme 6).22 The bromodiol 4 obtained from bromobenzene via 
bacterial dioxygenase of Pseudomonas putida, was protected with 2,2-DMP to yield 62. 
The Cbz-protected oxazine 63 underwent reduction cleavage of N-O to afford 64 using 
aluminum amalgam. The closure of 65 were first done using Chida’s conditions,21 
unfortunately it cannot be reproduced, therefore a modified Heck cyclization with 
15 
 
Pd(OAc)2 , Tl(OAc), and DIPHOS was used to yield the desired product 66. The total 
synthesis of lycoricidine was achieved in 9 steps.  
2.1.4. Synthesis of Analogues of Narciclasine and Lycorcidine 
Although these Amaryllidaceae alkaloids are potent, the problem of insolubility 
has halted the possibility of using this class of compounds as a therapeutic. There have 
been extensive studies towards finding possible analogues, not only with the same 
potency, but solving the problem of solubility. This section will briefly cover total 
syntheses of different narciclasine and lycorcidine  analogues from Banwell,24,25 
Chapleur,26,27 and Kim.28  
Banwell published the total synthesis of ent-narciclasine in 2008.24 To assemble 
the aromatic core the majority of the procedures were taken from Keck’s total synthesis 
of narciclasine.12 The aldehyde 35 (Scheme 7) is carefully functionalized by first 
transforming the aldehyde to an ethyl amine, directed ortho-methalation to add the 
hydroxyl and the iodide resulting compound 67. The conversion of the ethyl amine to 
the ester resulted in the cleavage of the TBS group and therefore MOM-Cl was used to 
protect the hydroxyl before the compound was subjected to the Miyaura borylation to 
afford 68. The assembly of the C-ring core begins with cis-bromodiol 69. In order to 
obtain 70, the diol is protected as a cis-1,2-dihydroxylatio, done using UpJohn 
conditions, which proceeds with excellent regio- and diastereo-control. The alcohol 
groups were protected with MOM, reductive cleavage is performed by DIBAL-H to 
remove PMP. To selectively deprotect the desired hydroxyl DDQ was used and in turn 
16 
 
microwave-promoted Overmann rearrangement followed by DIBAL-H reduction was 
carried out to afford the free amine 71. Compounds 68 and 71 are the key building 
blocks of this total synthesis and in order to generate the narciclasine skeleton, Suzuki-
Miyaura cross coupling under a microwave irradiation was performed. Global 
deprotection with TMS-Br afforded ent-narciclasine 72. The total synthesis took 11 steps 
at an overall yield of 26%.   
 
a) sec-BuLi, TMEDA; b) B(OMe)3, H2O2, AcOH; c) TBS-Cl, imidazole; d) sec-BuLi, TMEDA, I2  
e) Na2HPO4 , Me3O+BF4 –;   f) MOMCl;  g) pinacolatoborane, PdCl2, dppf; h) p-MBDMA, 
p-TsOH; i) OsO4/NMO; j) MOM-Cl; k)DIBAL-H,MOM-Cl; l) DDQ;  m) Cl3CCN,DBU  
n) K2CO3, μwave, 165 °C; o) DIBAL-H; p) Pd[0], base, μwave; q) TMS-Br 
 
Scheme 7- Banwell’s Total Synthesis of ent-narciclasine 
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 Chapleur and colleagues set out to investigate an efficient approach of the 
formation of the C-10a-C-10b bond (Scheme 8).26 In order to achieve this goal, o-
metalation of the amide 73 reacted with the lactone 74 to form the diols 75. The 
conversion of 75 to the aldehyde 76 occurred using of sodium periodate. The cyclization 
of 76 formed a mixture of elimination product 77 and diol 78. Both compounds were 
converted to the desired product 79 by refluxing in thiophenol and trimethylamine. 
Compound 79 was treated with methanol and ammonia, sodium cyanoborohydride, and 
formic acid to yield compounds 81, 82 (25%), 83 (20%), and 84.  
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a) sec-BuLi, THF, -78 °C, 70%; b) AcOH-H2O, THF, reflux, 90%; c) MeOH, NaIO4, H2O; d) 
Na2CO3, DBU, 70%; e) Ac2O, pyridine, 92%; f) PhSH, NEt3, THF, reflux, 86%; g) NH3, 
MeOH; h) NaBH3CN, HCOOH, CH3CN; i) Ac2O, DMAP, pyridine  
Scheme 8- Chapleur’s Narciclasine Analogues 
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a)i) NaBH4, CeCl3, EtOH, rt; ii) THF, Dowex H+ resin; b) i) Ac2O, pyridine, 70 °C; ii) Tf2O, 
CH2Cl2, pyridine, -30 °C; iii) TFA, THF/H2O, reflux; iv) MOMCl, iPr2NEt, CH2Cl2, rt; v) NH3, 
MeOH, 0 °C then rt; vi) NaBH3CN, HCO2H, CH3CN, reflux; c) i) Tf2O, DMF, -30 °C, 1 h then 
NaN3; d) i) NH2OMe, HCl, THF, reflux; ii) L-Selectride, THF, -30 °C; iii) TFA, THF/H2O, 
reflux; iv) MOM-Cl, iPr2NEt, CH2Cl2, rt; v) NH3, MeOH, 0 °C then rt; vi) NaBH3CN, HCO2H, 
CH3CN, reflux; iv) MeONa, MeOH, rt; AcOH, H2O 9/1, TFA, reflux. 
Scheme 9- Chapleur’s Lactone Narciclasine Analogues 
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 In the year 2004, Chapleur prepared more lactone analogues (Scheme 9).27 
Compound 85 was exposed to two different conditions to afford both 86 and 88 with 
1:1 mixtures. The cyclization did not occur in basic conditions, therefore acidic 
conditions were done to deprotect the acetonide and it promoted the wanted product 
87 and 88. These analogues were sent for testing against L1210 cell lines, but did not 
show any activity.  
 
 
 
a) CHBr3, 50% aq NaOH, C6H6, TEBAC, 0-18 °C; b) i) AgOCN, 1 ,4-dioxane, 100 °C; ii) 
NaOMe-MeOH 18 °C; c) i) Pd(PPh3)4, C6H6, EtOH; ii) Na2CO3 , HCl, THF; d) i) (MeCO)2O, 
DMAP, C5C5N, CH2Cl2, 18 °C; ii) Tf2O, DMAP, CH2Cl2, 0-15 °C; iii) HCl, THF; iv) Ac2O, DMAP, 
pyridine; e) NaOMe, MeOH, THF  
Scheme 10- Banwell’s Lycoricidine Analogues 
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 Banwell’s synthesis of lycoricidine analogues began with the starting material 
cyclopentadiene was converted to diols while Pb(OAc)4–mediated oxidation, and 
transformed into the cyclohexanone acetal 90 (Scheme 10).25 In order to produce 91, 
dibromocarbene reacted with the olefin using Makoza conditions producing the 
steroselective tricyclic adduct. Silver isocyanate was used for ring opening of 91 to 
produce 92, which was isolated using medium pressure liquid chromatography (MPLC). 
Suzuki cross coupling was performed on the boronic acid 93 and the carbarmate 92 to 
afford the styrene 94. The Bischler-Napieralski cyclization was performed in order to 
obtain the final lycoricidine skeleton. After the deprotection steps 96 was obtained in 8 
steps.  
 McNulty’s approach to 3-deoxydihydrolycoricidine began with cycloaddition of 
nitrostyrene 97 and Danishefsky’s diene 98 to provide the cyclohexanone 99, Scheme 
11.29 The ketone was reduced to alcohol 101 with the use of sodium borohydride and 
with a modified Mitsunobu protocol 102 was produced. The nitro group was then 
reduced and converted to the carbamate by aluminum amalgam 103, which was 
exposed to Bischler-Napieralski reaction, demethylation, and removal of the ester 
provided 3-deoxy trans-dihydrolycoricidine 105.    
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a) 98, PhMe, 110° C; b) NaBH4, EtOH; c) 100, Bu3P=C(CO2Me)2, PhCH3, 70% for 3 steps; d) 
i) Al(Hg), EtOH, H2O; ii) ClCO2Me, pyridine, CH2Cl2,70%; e)Tf2O, DMAP, 65%; f) i) BI3, 
CH2Cl2, 15%; ii) LiAlH4, THF. 
Scheme 11- McNulty’s 3-deoxydihydrolycoricidine Synthesis  
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2.1.5. Biological Studies and Anti-cancer Activity of Amaryllidaceae Alkaloids 
In order for a compound to be classified as a therapeutic, an intense and 
vigorous process of understanding the pharmacophore must be done. As mentioned 
earlier, members of the Amaryllidaceae family has been used in traditional folk 
medicine for a wide range of cancer related illnesses. During modern times, Ceriotti30 
was the first to report narciclasine 1 to have antimitotic activity on Sarcoma 180 and 
inhibition of wheat grain radicles. With the use of anti-cancer assays, murine P-388 
lymphocytic leukemia, there was the isolation of a few isocarbostyril Amaryllidaceae 
alkaloids. These alkaloids had low ED50 and were found to exhibit activity against a 
variety of cancer cell lines in vitro and in vivo.8 Amaryllidaceae alkaloids 1,2 and 12-15 
displayed antiviral activity in vitro against a number of flaviviruses such as Japanese 
encephalitis, yellow, and dengue fevers.31  Pancratistatin, narciclasine and 7-
deoxypancratistatin display activity in vivo with mice infected with Japanese 
encephalitis; to date few treatments have been discovered for this rare disease.  
Table 1- Biological Activity of Selected Amaryllidaceae Compounds 
Compound Mean GI50 (µM) 
Narciclasine 1 0.016 
Pancratistatin 2 0.091 
Lycoricidine 12 0.15 
7-deoxypancratistatin 13 0.100 
trans-dihydronarciclasine 14 0.0126 
trans-dihydrolycoricidine 15 0.0676 
 
 The National Cancer Institute (NCI) conducted an in-depth study with standard 
MTT colorimetric assays with diverse human tumor cell lines for different 
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Amaryllidaceae alkaloids. Narciclasine 1, exhibited potent cytotoxicity against human 
cell lines and murine P388 leukemia cells (Table 2).32, 33  In comparison with narciclasine 
1 (mean IC50= 0.046 µM), lycoricidine 12 demonstrated cytotoxicity 10 times weaker 
(mean IC50= 0.33 µM) and pancratistatin 2 was five times weaker (mean IC50= 0.26 
µM).33 Focusing on the Leukemia P388 cell line, dehydronarciclasine 12 has more potent 
cytotoxicity than narciclasine, but dehydrolycoricidine 13 is at the same level as 
lycoricidine (Table 2).  
 In order to develop successful therapeutics, pharmacology plays an important 
role. In terms of the C-ring, any removal or alteration of C2-C4 yields compounds that 
are inactive or possess poor activity (see Table 3). For the B-ring, the amide bond (C6-
C5) is crucial; if the N5 is replaced with an oxygen or the nitrogen is removed all activity 
is lost. Removal of the C7-hydroxyl of the A-ring results in the loss of one order of 
magnitude in activity. With years of literature precedence in terms of biological activity 
the only possibility of alternations is C10 and C1 pancratistatin analogues.  
Table 2- In Vitro Cytotoxic-Related Antitumor Effects of Naturally Occuring Isocarbostryil 
Alkaloids (IC50 Values in µM) 
Compounds Cancer Cell Lines 
 Leukemia 
P388 
Pancreas 
BXPC-3 
Breast 
MCF-7 
CNS 
SF268 
Lung-NSC 
NCI-H460 
Colon 
KMS0L2 
Prostate 
Du-145 
1 0.042 0.011 0.010 0.010 0.027 0.011 0.011 
2 0.052 0.061 0.071 0.043 0.098 0.077 0.046 
12 0.065 0.24 0.16 0.41 0.18 0.29 0.17 
13 1.42 NT NT NT NT 0.71 NT 
 
 
 
26 
 
 
Table 3- Examples of Amaryllidaceae Analogues 
Compound Mean Value of 
IC50 (µM) 
Alteration from 
Lead 
Structure(1 & 2) 
Reference 
 
106 
Inactive No hydroxyls on 
C1-C3, and C7 
34 
 
107 
2.3 No hydroxyls on 
C1, C4, and C7 
34 
 
108 
Inactive No hydroxyls 
C1, C3, and C7 
29 
 
109 
Inactive No hydroxyls 
C1, C2, and C7 
35 
 
110 
Inactive Aromatic C-ring 28 
27 
 
 
111 
Inactive No 10a-10b 
bond 
36 
 
112 
Inactive No amide 
oxygen 
37 
 
113 
5.7 No amide 
oxygen 
37 
87 Inactive Oxygen replaces 
the nitrogen 
27 
88 Inactive Oxygen replaces 
the nitrogen 
27 
 
114 
Inactive  No amide 
fragment 
opening of the 
B-ring 
38 
 
115 
12.5 No methylene 
dioxy bridge 
35 
28 
 
 
 
116 
Inactive No methylene 
dioxy bridge 
39 
 
117 
Inactive No methylene 
dioxy bridge 
39 
 
Straden et.al. did an extensive review on the mechanistic insights to the 
cytotoxicity of Amaryllidaceae alkaloids.40 Narciclasine was seen inhibiting protein 
synthesis in rabbit reticulocytes and yeast cell-free systems by halting peptide formation 
on the ribosome level. It was also shown that narciclasine binds to the peptidyl 
transferase centre of the 60S ribosomal unit (Figure 7).41 
 
Figure 7- Narciclasine and Lycorine binding to the 60S tRNA P-site41 
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2.2. Aromatic dioxygenases 
2.2.1. Discovery of aromatic dioxygenases 
Cyclohexadiene diols are a useful starting material and can be utilized in 
syntheses of carbohydrates, inositols, alkaloids, and terpenes.42,43 Synthetic organic 
chemists are always looking for a process that is not only efficient, but reproducible and 
the promise of large quantities of a product. In 1968, Gibson studied oxygen fixation and 
microbial oxidation on aromatic compounds, such as benzene and toluene by 
Pseudomonas putida strain.44 The rate of metabolism of these aromatic compounds 
needed to decrease, therefore Gibson exposed p-chlorotoluene 118 to the organism 
grown with toluene to produce the first stable cyclohexadiene diol 119 (Figure 8).45 
 
Figure 8- Formation of cis-4-2,3-dihydroxy-1-methyl benzene from p-chlorotoluene with 
Pseudomomas putida F1 
The dihydroxylation process was an interest to chemists in order to fully understand the 
transformation that took place during the fermentation. An experiment was conducted 
where the fermentation process was carried out in the presence of 18O2. Using mass 
spectroscopy the products were analyzed and the outcome was the material increased 
by four mass units, which indicated the both oxygen atoms originates from the same 
oxygen molecule (Figure 9).46 
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Figure 9- Proposed Mechansim of diol formation 
In 1989 Gibson isolated the genes that were responsible for the toluene dioxygenase 
enzyme complex, which was cloned and expressed into Escherichia coli.17b This was 
beneficial because it is easy to grow and ferment E. coli and allow the opportunity for 
better enzyme concentration because of the incorporation of these plasmids.  
2.2.2. Utilization of diols in the natural product synthesis  
The first use of these diols in natural product synthesis was by Ley,47 but this 
section will highlight enantiodivergent synthesis of pinitol by Hudlicky which was 
achieved by using the same bromodiol 4.48 Once 4 was protected with an acetonide 62 it 
was subjected to selective osmylation 123 (Scheme 12) and reductive removal of the 
bromide 124. The expoxidation was carried out by using mCPBA with 125 followed by 
the use of methanol and aluminum oxide to yield the methyl ether 126. The synthesis of 
(+)-pinitol 127 was achieved in 6 steps. Hudlicky took advantage of the latent symmetry 
of the diol 62 and was able to carry out the synthesis of (-)-pinitol (Scheme 13) by 
epoxidation of 62 to obtain 128 and using the same methodology as 127, (-)-pinitol was 
also obtained in 6 steps.      
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a)i) 2,2-DMP, TsOH; ii) OsO4 , NMO, acetone, H2O, 85%; b) LAH, THF, 85%; c) mCPBA, 
CH2Cl2, 85%; d) MeOH, Al2O3 , 90%; e) HCl, H2O, acetone 
Scheme 12- Hudlicky’s Synthesis of (+)- Pinitol 
 
a) mCPBA, CH2Cl2, 80%; b) i) MeOH, Al2O3; ii) LAH, THF, 76%; c) i) OsO4 , NMO, acetone, 
H2O, 85%; ii) HCl, H2O, acetone, 64% 
Scheme 13- Hudlicky’s Synthesis of (-)-Pinitol  
 Since the first introduction of cis-cyclohexadiene diols these synthons have been 
used as starting materials in a large number of natural products (Table 4). The diols have 
allowed the construction of complicated molecules in fewer steps than other simple 
starting materials. The cis-cyclohexadiene diols can be prepared in large quantities and 
with different functional groups which allows an array of possibilities of what can be 
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used with.  The stereochemistry of these synthons allows the diastereoselective 
preparation of different classes of natural products.  
Table 4- Synthetic targets accessed using cyclohexadiene diol  
Compound 
 
 
 
 
 
 
(±)-Pinitol                                               
13147 
 
 
 
 
 
 
 
Prostaglandin E2 
13249 
 
 
 
 
 
 
 
(+)-Armillarivin 
13350 
 
 
 
 
 
 
 
(+)-Phorbacin C 
13451 
 
 
 
 
 
 
Oseltamivir 
13552 
 
 
 
 
 
 
Carba-β -L-glycopyranose 
  13653 
 
 
 
 
 
 
Brunsvigine 
13754 
 
 
 
 
 
 
Conduritol C 
13855 
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L-threo-sphingosine 
13956 
 
 
 
 
 
Asorbic Acid 
14057 
 
 
 
 
 
 
 
 
Nangustine 
14158 
 
 
 
 
 
 
 
 
Morphine 
14259 
 
 
 
 
 
 
 
 
ent-codeine 
14360 
 
 
 
 
 
 
 
 
ent-hydromorphone 
14461 
 
 
 
 
 
 
 
 
Codeine 
14562 
 
 
 
 
 
 
 
 
(+)-trihydroxyheliotridane 
14663 
 
 
 
 
 
(−)-trihydroxyheliotridane 
14763                                         
 
 
 
 
 
(−)-hisutene 
14864 
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2.2.3. Synthesis of 10-azanarciclasine 
The route for the azanarciclasine series was initially derived for the 7-
azanornarciclasine and the same intramolecular Heck approach and identical 
conduramine 7 can be used for the synthesis of 151 (Figure 10).65  
 
Figure 10- Retrosynthesis Analysis of 7-azanornarclasine 
The construction of the C-ring was well known from previous research in the 
group; however finding an approach to the A-ring that is efficient and short was a 
challenge (Figure 11).66 It was thought that 153 could be obtained by exposing 156 to 
halogen dance conditions using a strong base and quenching the anionic intermediate 
with CO2.  Directed ortho-lithiation of 155 and sequential borylation, oxidation and 
methylation will provide the bromopyridine 154.    
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Figure 11- Retrosynthetic Analysis of 10-azanarciclasine 
The most efficient method to produce pyridine 154 was directed ortho-lithiation of 155 
then submitted to borylation with B(OMe)3 and in situ oxidation. Compounds 155a and 
155b were not isolated, but the reactions were monitored by TLC and 154 was obtained 
after 155b was exposed to diazomethane. The oxidation step is sensitive to water, 
therefore it was hypothesized that instead of using the usual oxidant 30% H2O2 , due to 
protodeborylation, urea hydrogen peroxide was a better candidate. Also other 
methylation agents were used, for example dimethylsulfate, methyl iodide, and 
Meerwein’s salt but only diazomethane proceeded to selectively methylate the 4-
pyridinol 155b.  
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a) LTMP,THF, -78 °C; b) B(OMe)3; c) i) AcOH, UHP; ii) CH2N2, THF, 36% 
Scheme 14- Synthesis of key intermediate 154 
Having obtained the key intermediate 154, the uncertain section of the total synthesis 
was the halogen dance (also known as halogen scramble). In order to achieve halogen 
dance there are a few key requirements: i) low temperatures; ii) no excess sub-
stoichiometric base; iii) the base must be added to the halide; iv) using THF as a solvent; 
v) a slow reacting electrophile (alkyl halides and DMF).67 Using these guidelines the 
aryllithium intermediate 156 was quenched with three electrophiles, methanol 157, 
DMF 158a and CO2 157 (Scheme 15). Proton NMR was used to provide sufficient 
evidence that the halogen dance indeed did occur. 
 
Scheme 15- Halogen Dance Reaction 
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Once the reaction conditions were established instead of using DMF as an electrophile 
quench CO2 was added and lithium carboxylate 157 was not isolated but immediately 
moved forward to the HBTU coupling 152 (Scheme 16). The intramolecular Heck 
reaction would only occur if there was a bulky protecting group present on the nitrogen, 
therefore Boc was added to 152 and left stirring overnight to yield the precursor 158. 
Reactions were screened on similar heterocyclic analogues (Table 5) that allowed us to 
determine which conditions would be appropriate for 158.65 The reaction mixture was 
monitored by TLC and the fully protected 10-azanarciclasine 159 was obtained.  
 
a) i) LTMP, THF, -80°C; ii) CO2; b) 7, HBTU, DIPEA, MeCN, 30% for 2 steps; c) Boc2O, 
DMAP, MeCN, 80%; d) Pd(OAc)2, dppe, Ag3PO4, Cs2CO3, PhMe, 90°C, 58%. 
Scheme 16- Synthesis of Fully Functionalized Skeleton of 10-azanarciclasine  
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Conditions  Outcome  
Pd(dppf)2Cl2, dppf, Ag3PO4 dioxane, 60°C, 24 h No reaction 
Pd(OAc)2, dppe, Ag3PO4, Et3N toluene, 80oC, 
18 h 
Traces of product  
Pd(OAc)2, PPh3, Et3N, AgNO3, MeCN, 24 h, r.t 
to 80oC 
No reaction 
Pd(OAc)2, dppe, AgNO3, Cs2CO3, toluene, 24 h, 
110oC 
Mixture  
Pd(OAc)2, BINAP, Ag3PO4, Et3N toluene, 80oC, 
18 h 
No reaction 
 
Table 5- Screening for Intramolecular Heck for 149 
 
 The deprotection of sequence for 159 is described in Scheme 17. Demethylation 
of the pyridinol was brought about through the use of lithium chloride at high 
temperatures to afford 160. Once the product was isolated it was subjected to standard 
desilylation conditions in the presence of TBAF to yield alcohol 161. Different 
deprotection conditions were investigated to remove the acetonide and Boc groups. HCl 
in methanol led to decomposition of the material, but when the weaker formic or 
trifluoroacetic acid, there was no deprotection. To solve this problem wet trifluoroacetic 
acid (H2O 5% v/v) was used to obtain 10-azanarciclasine 151 in 11 steps (9 one-pot 
reactions).  
39 
 
a) LiCl, DMF, 100°C, 56%; b) TBAF, THF, 90%; c) TFA, H2O, CH2Cl2, 77%. 
Scheme 17- Deprotection of 10-azanarciclasine 
3. Discussion 
3.1.1. Synthesis of 7-aza-10-methoxy-narciclasine 
Natural products have been a significant and convenient source for new 
therapeutics. Amaryllidaceae alkaloids, in particular the isocarbostyril family, are known 
to be compounds with high activity, with the possibility to be worthwhile drug 
candidates. The concerns associated with this class of compounds is the limited 
availability from natural sources and the meagre solubility profiles. Although the issues 
of solubility have been addressed maintaining activity is still a problem, therefore the 
generation of these derivatives still relies on the supply of natural sources. The main 
objective of this project is to produce a new class of heteroanalogues that resolve the 
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problem of solubility and activity, through an efficient and divergent route to 
narciclasine. In order to achieve this goal a common, abundant starting material must be 
chosen and a synthetic plan that has the least amount of steps possible.  
The major theme of this discussion will be the utilization of the bromodiol 4 for the 
approach to the total synthesis of 7-azanarciclasine 9. Despite the two analogues having 
the same starting materials, a divergent strategy was applied to arrive at the two 
isomeric products.   
 
Figure 12- Synthetic Strategy for 10-azanarciclasine and 7-azanarciclasine 
Our attention turned to using the same methodology described in the historical 
of 10-azanarciclasine to synthesize 7-azanarciclasine 9 (Figure 12). The unique portion of 
the synthesis of the 10 and 7-aza series was the transformation of furfural 5 to the 
pyridine diol 6, using a procedure published by Dallacker (Scheme 18).68 The yield for 
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the installation of the methylene bridge in 155 is surprisingly low, but when compared 
to literature examples it is seen to be around 20% one can assume the nitrogen hinders 
the reaction unlike having a simple aromatic ring. The reaction mechanism for this 
transformation is unknown, therefore we proposed a mechanism (Figure 13). 
Electrophilic addition of Br2 occurs at the more electron rich alkene of the furan ring 5. 
Lone pair assisted elimination of bromide forms a cation which is attacked by H2O III. 
Acid catalyzed ring opening results in an enol which eliminates the second bromide to 
yield cis alkene VI. A second bromination yield the dialdehyde VIII, which reacts with 
sulfamic acid to give bis-aminal IX, which eliminates water to yield enamine XI. 
Elimination of bromide via the enamine and tautormization yields XIII, which upon loss 
of SO3 yields the desired product 6. 
 
a) i) 1 eq. Br2, H2O, 0 °C; ii) HCl, H2O, 0 °C; iii) 1 eq. Br2, 0 °C; iv) H2NSO3H, 50 °C, 65%, b) 
CH2Br2, K2CO3, CuO, DMF, 95 °C 18%. 
Scheme 18- Synthesis of intermediate 155 
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Figure 13- The Hayward-Hudlicky Modification of the Vshyvenko Hypothesis 
 
The formation of oxazines is well known in the Hudlicky group, therefore the 
synthesis of the C-ring in principle was quite simple (Scheme 19). The bromodiol 4 
reacted with BocNHOH using NaIO4 as an oxidant in a hetero-Diels-Alder type reaction 
to yield 163. Aluminum amalgam was prepared and selectively cleaved the C-Br and N-O 
bonds to form 164. The hydroxyl was protected with TBS 165 and the Boc was cleaved 
using TFA and the amine 7 for coupling.  
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a) BocNHOH 169, NaIO4, 0°C to rt, 74%; b) Al(Hg), THF/H2O, 89%; c) TBS-Cl, imidazole, 
CH2Cl2, 81%; d) TFA, CH2Cl2, 0°C, 86%. 
Scheme 19- Construction of the C-ring 
During the synthesis of 10-azanarciclasine the deprotection of Boc 165 was often 
problematic in terms of selectivity between the three acid-labile protecting groups. 
Selective deprotection of the Boc group was only observed on rare occasions despite 
strict efforts to maintain the conditions. The different reaction conditions done were 
summarized in Table 6. In order to obtain consistency with this system the final decision 
was made to change the protecting group on the oxazine.  
Table 6- Screening of Deprotection Conditions 
Reaction Conditions Outcome 
TFA, 0°C, CH2Cl2 , 20 min Removal of acetonide 
TFA, 2,2-DMP,0°C, 4Å Sieves, CH2Cl2 Starting Material 
TFA:CH2Cl2 (1:4) , 20 min Mixture of product (7) & no acetonide 
Silica gel, CH2Cl2, H2O, 140°C, 24 h No reaction 
TMSOTf, NEt3, CH2Cl2 , 0°C to rt No reaction 
 
 Scheme 20 outlines the new synthetic route for the C-ring.  Although it 
eliminated the problem of selective de-protection new issues arose. The production of 
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the oxazine 166 was performed as before, BocNHOH replaced by TrocNHOH. This 
structure was interesting to us and was sent for crystal structure to prove the 
stereochemistry (Figure 13). Using aluminum amalgam was attractive considering in 
literature Troc had the potential to eliminate using electrode Al(Hg) at −1.7V, thus 
would result in the acetonide-protected conduramine in one cleavage step. Our 
hypothesis was proven to be correct and using proton NMR it was determined that Troc 
was being eliminated to produce the desired product 49. Table 7 summarizes different 
reduction conditions that have been tried. It was observed 49 was not stable, therefore 
all precautions were taken by deactivating the silica with NH4OH during the purification 
process. Unfortunately the impurity associated with compound 49 still can be seen on 
TLC.   
 
 
a) TrocNHOH 170, NaIO4, 0°C to rt, 72%; b) Al(Hg), THF/H2O, 30% 
Scheme 20- Synthesis of the Oxazine 
Table 7-Reduction of 166 
Reaction Conditions Outcome 
SmI2, HMPA, rt, 8 h No reaction 
Al(Hg), THF/H2O, 2 h 30% product 
Zn, MeOH No reaction 
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Figure 13- Crystal Structure of 166 
There is literature precedent that discusses the difficulty of fully functionalizing a 
pyridine ring due to the nitrogen, therefore finding an efficient synthetic route  was a 
problem.69 For 10-azanarciclasine, the carboxylate needs to be installed in the 3-position 
and in-situ the amide coupling reaction was carried out. For this alkaloid, the same route 
was taken by blowing in CO2 through a drying agent or adding in dry ice pellets, but the 
carboxylate did not form in the  
2- position of the pyridine ring. A different route was taken where after the lithiation the 
reaction was quenched with DMF 167, Pinnick oxidation was done using Fukuyama 
conditions to yield 8.70 The purification of the carboxylic acid was trying, recrystallizing 
with a few different solvents was attempted but was not successful. The purification of 
8 using column chromatography was attempted, but unfortunately decomposed on the 
column. Due to the problems of reproducibility of 7 and stability of 49 the total 
synthesis of 7-azanarciclasine could not be achieved. 
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a) LTMP, DMF, -78°C, 52% ; b) NaClO2 , NaH2PO4 , 2-methyl-2-butene, t-BuOH, H2O, 80%; 
c) 7, HBTU, DIPEA, MeCN, 45%. 
Scheme 21- Synthetic Route to the A-ring and Coupling  
 
4. Conclusion and Future Works 
The successful synthesis of 10-azanarciclasine orchestrated by Dr. Sergey Vshyvenko for 
this family of compounds, and solubility measurements validate our analog design 
concept. However, the biological activity of this analog was decreased from the parent 
compound, which led us to undertake the synthesis of 7-azanarciclasine. Unfortunately 
this synthesis has not reached completion because of the different regiochemistry of the 
pyridine ring and the difficulties of the reliability of selective deprotection of the 
conduramine C-ring. This has led to us exploring different protection strategies for this 
ring system, which should lead to the successful synthesis of 7-azanarciclasine and its N-
oxide analogues.  
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5. Experimental 
5.1. General Experimental Details 
Reactions were carried out under inert atmosphere in flame-dried glassware unless 
stated otherwise. Solvents were distilled prior to use: CH2Cl2 from CaH2, DMF from CaH2, 
and THF from Na/benzophenone. Thin layer chromatography was performed with pre-
coated silica gel aluminum sheets (EMD silica gel 60 F254), detection by UV and with 
“CAM” solution (5 g of (NH4)6Mo7O24·4H2O, 1 g of Ce(SO4)2, 100 mL of 10% H2SO4) or 
0.5% aqueous KMnO4 solution followed by heating. Flash chromatography was 
performed using silica gel SiliaFlash P60 or F60 from Silicycle (40–66 μm). Optical 
rotation was measured in a 1-dm cell at 20-25 ˚C and 589 nm, concentration c in g/100 
mL. IR spectra were collected on a Bruker Alpha IR spectrometer equipped with a 
Platinum ATR module. 1H NMR and 13C NMR spectra were recorded at Bruker Avance I 
300, Bruker Avance III HD 400, and Bruker Avance I 600 and 75 MHz, 100MHz, and 150 
MHz, respectively, and were calibrated on the solvent residual peak (CDCl3 = 7.26 ppm; 
CD3OD= 3.31), the chemical shifts are reported in ppm. Data are reported as s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br = broad; coupling constants (J) in 
Hz, integration. 
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5.2. Detailed Experimental Procedures 
2,3-Dihydroxy-5-Bromopyridine (6). 
 
Freshly distilled furfural (24.4 mL, 254 mmol) and crushed ice (175 g) were stirred and 
cooled to 0-2 °C. Bromine (13 mL, 255.5 mmol) was added dropwise via an addition 
funnel over 40 min. concentrated HCl (37%, 21 mL) was added  and the reaction mixture 
stirred for 30 min maintaining the temperature at 0 °C ,  after which a second portion of 
bromine  (13 mL, 255.5 mmol) was added dropwise. Once the reaction was complete 
the mixture was filtered and the straw yellow filtrate was transferred into a flask. 
Sulfamic acid (37.5 g, 386 mmol) was added and the mixture was heated to 50 °C for 1.5 
h. The reaction mixture was filtered and the solid transferred to a crystallization dish, 
treated with distilled water (5 mL) and dried in the oven overnight.  The product was 
dissolved in AcOH (400 mL) ,charcoal pellets were added and the mixture was heated to 
40 °C for 3 h, after which the charcoal was removed by filtration and the filtrate was 
allowed to cool down to room temperature, placed in an ice bath, and crystals was 
collected. The product was obtained as grey crystals (52.3 g, 68 %).  
6: mp 245 °C (AcOH), [lit.68 249 °C (AcOH) 
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6-Bromo-[1,3]dioxolo[4,5-b]pyridine (155). 
 
2,3-Dihydroxy-5-Bromopyridine 6 (25.9 g, 0.137 mol), DMF (40 mL), K2CO3 (47.3 g, 0.343 
mol), copper(II) oxide (3.29 g, 0.0411 mol), and dibromomethane (19.14 mL, 0.274 mol) 
were combined and left stirring under argon for 15 min. The reaction mixture was 
heated to 95 °C for 16 h under an inert atmosphere. The mixture was filtered and the 
filtrate was collected and diluted with H2O (500 mL); a white precipitate was formed and 
second filtration was conducted. The precipitate was discarded and the filtrate collected 
was extracted with EtOAc (3 x 200 mL), the combined organic layers were concentrated 
under reduced pressure. The product was purified by flash column chromatography 
(hexanes/EtOAc 4:1) affording 155 a white solid (5.22 g, 25%). 
155: Rf 0.7 (hexanes/EtOAc 2:1); mp = 67-69 °C (EtOH), [lit.66 69-71° C]; 1H NMR (300 
MHz, CDCl3) δ  7.71 (s, 1 H), 7.12 (s, 1 H), 6.09 (s, 2H) 1H NMR matched with lit. value.  
6-Bromo-7-methoxy-[1,3]dioxolo [4,5-b]pyridine (154). 
 
To a solution of 2,2,6,6-tetramethylpiperidine (0.64 mL, 3.8 mmol) in THF (5 mL) at -60°C 
n-BuLi (1.5 mL, 3.29 mmol) was added dropwise. Reaction mixture was stirred for 15 
min at -40 °C, then cooled down to -80 °C and a solution of 6-Bromo-[1,3]dioxolo[4,5-
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b]pyridine (0.52 g, 2.5 mmol) in THF (5 mL) was added dropwise, while maintaining the 
temperature at -80 °C. The reaction mixture was stirred for an additional 40 min, 
followed by addition of B(OMe)3 (0.70 mL, 6.25 mmol) and the reaction mixture was 
warmed up to 0 °C. The reaction mixture was then cooled to -60 °C and AcOH (0.43 mL, 
7.5mmol) was added, followed by addition of urea hydrogen peroxide (0.71 g, 7.5 
mmol) and stirred overnight at rt. Excess of urea hydrogen peroxide was quenched by 
NaHSO3 (sat. aq.), extracted with EtOAc (3×20 mL). The combined organic layers were 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
redissolved in THF:MeOH mixture (10:1, 30 mL) at 0 °C. The ethereal solution of 
diazomethane was added until the disappearance of starting material was observed by 
TLC monitoring. The reaction mixture was evaporated and the residue was purified by 
flash column chromatography (hexane/EtOAc 4:1) to yield 0.2 g of 154 (34%) as a yellow 
crystalline compound.  
154:Rf 0.45 (hexanes/EtOAc 5:1); mp  117-119 °C (CHCl3) [lit.66 69-71° C (CHCl3)]; 1H NMR 
(300 MHz, CDCl3) δ 7.72 (s, 0.75 H), 7.61 (s, 0.2 H), 6.08 (s, 2H), 4.19 (s, 3H); 1H NMR 
matched with literature.  
t-Butyl hydroxycarbamate (169). 
 
Hydroxylamine hydrochloride (9.6 g, 0.14 mol) and potassium carbonate (7.2 g, 0.069 
mol) in Et2O (60 mL) and H2O (4 mL) was stirred for 4 h at room temperature with 
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evolution of CO2.  A solution of di-t-butyl carbonate (20 g, 0.092 mol) in Et2O (40 mL) was 
added dropwise at 0 oC and the reaction mixture was stirred at room temperature for 7 
h. The organic phase was decanted and the solids were washed with Et2O and the 
organic solutions were combined and evaporated under reduced pressure. The 
compound was then recrystallized from pentane and toluene providing 169 as white 
crystals (8.1 g, 89%).  
169: mp 52-55 oC (pentane-tolune), [lit.71 58-59 °C (cyclohexane- tolune)];  
2,2,2-trichloroethyl hydroxycarbamate (170). 
 
Hydroxylamine hydrochloride (13.9 g, 0.200 mol) was added to a 1.5 M NaOH (160 mL, 
0.240 mol). The solution was cooled to 0 °C and 2,2,2-trichloroethyl chloroformate (5.30 
mL, 38.5 mmol) was added dropwise. The reaction mixture was stirred at room 
temperature for 2 h and acidified to pH 5 with conc. HCl. The resulting mixture was 
extracted with ether (5 x 200 mL), the combined organic layers were washed with brine 
(100 mL), then dried over MgSO4 and evaporated under reduced pressure. The crude 
product was then recrystallized with chloroform and hexanes to afford colourless 
crystals (5.85 g, 73%). 
170:Rf 0.1 (Hexanes/EtOAc 1:1); mp 88-91 °C (chloroform-hexanes), [lit.72 87-88 °C 
(benzene-light petroleum)];  
53 
 
(3aS,4R,7R,7aS)-2,2,2-trichloroethyl 4-bromo-2,2-dimethyl-3a,4,7,7a-tetrahydro-4,7-
(epoxyimino)benzo[d][1,3]dioxole-8-carboxylate (166). 
 
 To a solution of diol 4 (4.61 g, 24.2 mmol) in 2,2-dimethoxypropane (25 mL) was added 
a catalytic amount of p-toluenesulfonic acid in a flask. To improve the solubility of the 
reaction mixture, dichloromethane (25 mL) was added. To complete the consumption of 
starting material, the solution was cooled to 0 °C and after 70 min 10 mL of water was 
added. NaIO4 (5.62 g, 26.4 mmol) was added to the reaction vessel before 176 (5.53g, 
26.5 mmol) in 50 mL of methanol was added dropwise. After addition, the solution was 
warmed up to room temperature and stirred for 16 h.  Upon completion of the reaction, 
excess of saturated aqueous sodium bisulfite was added until a white color was 
obtained. The mixture was extracted with EtOAc (5 × 200 mL), the combined organic 
phase was washed with brine (2 × 15 mL) and dried over Na2SO4, and the solvent was 
removed in vacuo. The reaction product was purified by suction column 
chromatography73 (Hexanes/EtOAc 9:1,4:1, and 1:1) affording 7.27 g (72%) as a yellow 
solid. 
166:  Rf = 0.4 [(hexanes/EtOAc (1:1)]; mp 128-130 °C (CH2Cl2-pentane); [α]20D -1.51 (c = 1, 
CHCl3); IR (neat) ν 2989, 2955, 2934, 1711, 1435, 1413, 1381, 1343, cm-1; 1H NMR (600 
MHz, CDCl3)  δ 6.52 (d, J = 7.93 Hz, 1H), 6.45 (t, J = 7.17 Hz, 1H), 5.11 (s, 1H),4.85 (d, J = 
12.09 Hz ,1H), 4.72 (d, J = 11.33 Hz, 1H), 4.66 (s, 2H), 1.37 (s, 3H), 1.34 (s, 3H)  ; 13C NMR 
(75 MHz, CDCl3) δ 155.9, 134.2, 131.5, 111.8, 94.7, 87.5, 81.3, 75.5, 74.1, 53.6, 25.7, 
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25.5; HRMS (ESI) calcd for C12H14BrCl3NO5 [M+H]+ 435.9121:Found 435.9125; Anal. Calcd 
for C12H13BrCl3NO5: C, 32.94; H, 3.00. Found C (33.08); H (2.77) 
(3aR,4S,7R,7aS)-7-amino-2,2-dimethyl-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol 
(49). 
 
To a solution of 158 (1.08 g, 2.49 mmol) in THF:H2O (40:5 mL) was added aluminum 
amalgam, prepared by dipping small square strips of Al foil  (3.203 g, 31.4 mmol) 
sequentially to NaOH (1 M), distilled water, HgCl2 (0.5% solution), distilled water, and 
THF. The reaction mixture was stirred for 1 h and was filtered through sand and celite, 
washed with methanol (3 × 80 mL). The filtrate was concentrated, the residue was 
dissolved in toluene and concentrated for the second time. The product was isolated by 
flash column chromatography (CH2Cl2/MeOH/NH4OH 80:20:1) affording 0.118 g (26%) of 
49 as colourless viscous oil. 
49:  Rf = 0.4 [(CH2Cl2/MeOH (4:1)]; [α]
20  
𝐷
 =+3.45 (c = 1.18 , MeOH), [lit.14 [α]20  
𝐷
 = +11.2]; 
1H NMR (400 MHz, MeOD)  δ 5.80-5.75 (m, 1H),  5.67-5.64 (m, 1H),4.11-4.09 (m,2H), 
3.95-3.90 (dd, J =12.22, 5.58 , 1H), 3.22 (m, 1H), 1.44 (s, 3H), 1.36 (s, 3H);  
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 (3aS,4R,7R,7aS)-tert-Butyl 4-bromo-2,2-dimethyl-3a,4,7,7a-tetrahydro-4,7-
(epoxyimino)benzo[d][1,3]dioxole-8-carboxylate (163). 
 
To a solution of diol 4 (3.5 g, 18.3 mmol) in 2,2-dimethoxypropane (10 mL) was added a 
catalytic amount of p-toluenesulfonic acid in a flask. To improve the solubility of the 
reaction mixture, in acetone (5 mL).  The solution was cooled to 0 °C and after 15 min 
H2O (7 mL) was added followed by NaIO4 (5.52 g, 25.8 mmol) in one portion, after which 
a solution of t-butyl hydroxycarbamate (2.9 g, 0.022 mol) in MeOH (40 mL) was added 
dropwise. After addition was complete, the solution was allowed to warm to room 
temperature and stirred for 16 h. Excess of saturated aqueous sodium bisulfite was 
added carefully until a light straw color was obtained. The mixture was extracted with 
Et2O (3 × 100 mL), the combined organic phase was washed with brine (2 × 15 mL) and 
dried over Na2SO4, and the reaction mixture was concentrated under reduced pressure. 
The product was purified by flash column chromatography (hexanes/EtOAc 5:1) 
affording 163 a colourless solid (4.91 g, 74%) 
 163: Rf 0.6 (hexanes/EtOAc 2:1); mp = 150 °C (EtOH), [lit.66155 °C (EtOH)]; [α]
20  
𝐷
  = +2.0 
(c=2.5, CHCl3), [lit.66 [α]
20  
𝐷
= +25.3 (c = 1.0, CHCl3)]; 1H NMR (400 MHz, CDCl3) δ 6.50 (d, J 
=8.1 Hz, 1H), 6.40-6.38 (dd, J = 4.0, 3.5 Hz, 1H), 4.99-4.97 (m,1H), 4.61 (s, 2H), 1.47 (s, 
9H), 1.36 (s, 3H), 1.33 (s,3H) 1H NMR matched with literature. 
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t-Butyl ((3aS,4R,7S,7aR)-7-hydroxy-2,2-dimethyl-3a,4,7,7a 
tetrahydrobenzo[d][1,3]dioxol-4-yl)carbamate (164). 
 
 
To a solution of 163 (7.04 g, 19.4 mmol) in THF:H2O (140:14 mL) was added, aluminum 
amalgam was prepared by dipping small square strips of Al foil (4.94 g, 92.9 mmol) 
sequentially to NaOH (1 M), distilled water, HgCl2 (0.5% solution), distilled water, and 
THF. The reaction mixture was stirred overnight and then filtered through sand and 
celite, washed by methanol (3 × 220 mL). The filtrate was concentrated, the crude 
product was dissolved in toluene and concentrated for the second time. The product 
was isolated by flash column chromatography (hexanes/EtOAc 4:1) affording 4.93 g 
(89%) of 164 as colourless viscous oil. 
164:Rf 0.4 (hexanes/EtOAc 2:1); [α]
20  
𝐷
  = -1.2 (c=1.0, CHCl3) [lit.74 [α]
20  
𝐷
= -41(c = 1.0, 
CHCl3)];1H NMR (300 MHz, CDCl3) δ 5.92 (m, 1H), 5.80 (m, 1H), 5.04 (d, J = 7.0 Hz, 1H), 
4.23-20 (dt, J = 16.9, 6.0 Hz, 3H), 4.04 (m, 1H), 2.22 (s, 1H), 1.45 (s, 12H), 1.35 (s, 3H).1H 
NMR matched with literature. 
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tert-Butyl ((3aS,4R,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-3a,4,7,7a-
tetrahydro-1,3-benzodioxol-4-yl)carbamate (165). 
 
To a solution of 164 (1.94 g, 6.79 mmol) in CH2Cl2 (20 mL) was added imidazole (0.695g, 
10.2 mmol) followed by TBSCl (1.13 g, 7.48 mmol) at room temperat. After overnight 
stirring, the reaction mixture was quenched with water (35 mL), extracted with CH2Cl2 (3 
x 20 mL). The combined organic layers was dried with Na2SO4 and the solvent removed 
under reduced pressure. The product was purified by flash column chromatography 
(hexanes/EtOAc 8:1) affording 0.425 g (70%) of 165 as a white solid. 
165:Rf = 0.9 (hexanes/EtOAc 6:1); mp 102-105 oC (CHCl3); [α]
20  
𝐷
  = -2 (c=1.0, CHCl3) 
[lit.74[α]20  
𝐷
=-0.8 (c = 1.0, CHCl3),]; 1H NMR (300 MHz, CDCl3) 6.06-6.01 (m,  1H), 5.35 (d, 
J = 8.7 Hz, 1H), 4.32-4.28 (m, 3H), 4.19-4.16 (m, 1H), 1.48 (s, 9H), 1.37 (s, 3H), 1.31 (s, 
3H), 0.90 (s, 9H) 0.13 (s, 3H), 0.09 (s, 3H); 1H NMR matched with literature.66 
 (3aS,4R,7S,7aS)-7-((tert-butyldimethylsilyl)oxy)-2,2-dimethyl-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxol-4-amine (7). 
 
Trifluoroacetic acid (1.3 mL) was added dropwise to a solution of 165 (0.0497 g, 0.125 
mmol) in CH2Cl2 (5.2 mL) at 0°C. After 10 min the reaction was neutralised by the 
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addition of conc. ammonia (2 mL). The organic layer was extracted with CH2Cl2 (3 × 5 
mL), washed with brine (5 mL) and was evaporated. The free amine 7, 0.0364 g (80%), 
was obtained as a yellow oil and the sample was purified by flash column 
chromatography (Hexanes/EtOAc 1:1). 
7:Rf 0.4 (hexanes/EtOAc 1:1); [α]
20  
𝐷
 = -9.9 (c=1.0, CHCl3) [lit.66 [α]
20  
𝐷
=+15.5 (c = 1.0, 
CHCl3)]; 1H NMR (300 MHz, CDCl3)  5.73 (dt, J = 9.8, 2.3 Hz, 1H), 5.65 (dt, J = 9.8, 2.3 Hz, 
1H), 4.19-4.16 (m, 1H), 4.11 (dd, J = 7.8, 4.8 Hz, 1H), 3.89 (dd, J = 7.5, 6.3 Hz, 1H), 3.28 
(dd, J = 5.7, 2.1 Hz, 1H), 1.66 (s, 2H), 1.44 (s, 3H), 1.34 (s, 3H), 0.91 (s, 9H) 0.12 (s, 3H), 
0.11 (s, 3H) 1H NMR matched with literature.66 
6-Bromo-7-methoxy-[1,3]dioxolo[4.5-b]pyridine-5-carbaldehyde (167). 
 
A solution of 2,3,5,6-tetramethylpiperidine (0.33 mL, 1.94 mmol) in dry THF (15 mL) was 
cooled to −70 °C and n-BuLi (0.84 mL, 1.94 mmol) was added dropwise and the reaction 
mixture was warmed up to −30 °C. The reaction was then cooled to −70 °C and a 
solution of 6-bromo-7-methoxy-[1,3] dioxolo [4,5-b] pyridine (0.15 g, 0.65 mmol) 
dissolved in dry THF (2 mL) added dropwise over 30 min. After 30 min of stirring at −70 
°C, dry DMF (0.3 mL, 1.94 mmol) was added to the reaction mixture and kept at a 
constant temperature (-75 °C). The reaction was quenched with saturated NH4Cl(aq) and 
the mixture was extracted with EtOAc (3 × 10mL). The combined organic extracts were 
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then dried by Na2SO4 and the solvent evaporated under reduced pressure. The product 
was purified by flash column chromatography on silica gel (Hex/EtOAc 3:1) affording a 
lavender solid (0.0871 g, 52%). 
167:  Rf = 0.3 [(hexanes/EtOAc (2:1)]; mp 156 °C (MeOH); IR (CHCl3)  3583, 3349, 2961, 
2920, 1605, 1488, 1441, 1429, 1388, 1350, 1282, 1211, 1149, 1101, 1053, 1006, 961, 
918, 855, 772, 740, 666, 502, 471, 455 cm-1; 1H NMR (300 MHz, CDCl3)  10.13 (s, 1H), 
6.15 (s, 2H), 4.23 (s, 3H); 13C NMR (75 MHz, CDCl3)  188.7, 159.5, 145.1, 140.1, 130.6, 
112.9, 101.3, 60.1; MS (+EI) m/z 259 ([M, 79Br]+, 100), 261 ([M, 81Br]+, 98), 258 (18), 233 
(50), 231 (54), 215 (22), 186 (67), 132 (35); HRMS (ESI) calcd for 259.9558; found 
(259.9548); 
6-bromo-N-((3aS,4R,7S,7aS)-7-(tert-butyldimethylsilyloxy)-2,2-dimethyl-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxol-4-yl)-7-methoxy-[1,3]dioxolo[4,5-b]pyridine-5-
carboxamide (162). 
 
Aldehyde 167 (0.0230 g, 0.088 mmol) was dissolved in t-BuOH (3 mL) and H20 (1 mL). 
Sodium phosphate monobasic (0.0182 g, 0.132 mmol) and 2-methyl-2-butene (0.05 mL, 
0.44 mmol) are added to the reaction mixture and is cooled to 0 °C. Once reaching 
target temperature sodium chlorite (0.024 g, 0.27 mmol) is added and stirred for half an 
hour before removing the ice bath. After three hours starting material is completely 
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consumed and crude product was moved forward to the next reaction. Carboyxlic acid 8 
(0.0083 g, 0.030 mmol) was dissolved in dry MeCN (1.5 mL) , HBTU (0.013g, 0.033 mmol) 
was added, followed by DIPEA (0.01 mL, 0.060 mmol) and solution of amine 7 (0.0089, 
0.030 mmol) in MeCN (1.5 mL). Reaction mixture was stirred for five hours, quenched 
with NH4Cl (sat. aq., 2 mL) extracted with EtOAc (3 × 3 mL). Combined organic layer was 
dried over Na2SO4, evaporated subjected to flash column chromatography (silica gel, 
CH2Cl2/ MeOH 20:1) to yield 0.0075g (45%) of 162 as a beige crystalline compound. 
162:Rf 0.6 (CH2Cl2/ MeOH 20:1); mp 68-71°C (CHCl3); [α]
20  
𝐷
 =-15.2 (c = 1, MeOH); IR 
(neat, cm–1)  1608, 1506,  1461, 1370, 1257, 1210, 1103, 1059, 960 ;1H NMR (400 MHz, 
CDCl3) δ 7.61 (d, J = 8.9 Hz, 1H), 6.07 (s, 2H), 6.00 (dd, J = 9.7, 4.6 Hz, 1H), 5.92 (dd, J = 
9.7, 4.6 Hz, 1H), 4.69-4.67 (m, 1H), 4.37 – 4.35 (m, 1H), 4.27-4.24 (m, 2.25H), 4.20 (s, 
3.35H), 1.41 (s, 3H), 1.31 (s, 3H), 1.31 (s, 3H), 0.86 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 163.59, 157.73, 146.45, 140.06, 132.89, 129.64, 128.82, 
108.65, 106.76, 101.06, 68.61, 60.16, 47.94, 26.86, 25.96, 24.76, 18.30, -4.58, -4.66; ; MS 
(+EI) m/z (%) 421(7), 258 (13), 180 (63), 167 (28), 75 (94), 73 (47), 71(41), 69 (35), 57 
(100), 55 (50) ; HRMS (+EI) calcd for C22H30BrN2O7Si[M-C4H9, Br-81]:501.0517 Found: 
501.0519.   
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6. Appendix 
Table 8- Crystal Data and Structure Refinement for 166 
Identification code  zgii68_0m_b 
Empirical formula  C12 H13 Br Cl3 N O5 
Formula weight  437.49 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 8.6267(3) Å α= 90°. 
 b = 6.9749(2) Å β= 102.987(2)°. 
 c = 13.9151(4) Å γ = 90°. 
Volume 815.86(4) Å3 
Z 2 
Density (calculated) 1.781 Mg/m3 
Absorption coefficient 3.030 mm-1 
F(000) 436 
Crystal size 0.219 x 0.167 x 0.064 mm3 
Theta range for data collection 2.423 to 30.645°. 
Index ranges -12<=h<=12, -9<=k<=9, -19<=l<=19 
Reflections collected 23778 
Independent reflections 4969 [R(int) = 0.0309] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Numerical 
Max. and min. transmission 0.8676 and 0.6237 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4969 / 1 / 200 
Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0243, wR2 = 0.0514 
R indices (all data) R1 = 0.0333, wR2 = 0.0532 
Absolute structure parameter 0.020(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.552 and -0.423 e.Å-3 
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Table 9- Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103)for 166. U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
________________________________________________________________________________   
Br(1) 2878(1) 6000(1) 4013(1) 22(1) 
Cl(1) 9924(1) 6119(2) 9519(1) 40(1) 
Cl(2) 7341(1) 3714(1) 8500(1) 33(1) 
Cl(3) 10376(1) 3508(1) 7996(1) 32(1) 
O(1) 5891(2) 5551(3) 5018(1) 21(1) 
O(2) 7523(2) 4782(3) 2514(1) 27(1) 
O(3) 4854(2) 4621(3) 2371(1) 24(1) 
O(4) 9864(2) 6564(3) 6087(2) 33(1) 
O(5) 7672(2) 6079(4) 6708(1) 21(1) 
N(1) 7581(2) 5546(3) 5104(2) 21(1) 
C(1) 5108(2) 5996(5) 3997(2) 16(1) 
C(2) 5517(3) 4332(4) 3386(2) 18(1) 
C(3) 7335(4) 4385(4) 3486(2) 21(1) 
C(4) 8038(3) 6029(7) 4169(2) 23(1) 
C(5) 7252(4) 7891(4) 3793(2) 23(1) 
C(6) 5693(4) 7872(4) 3701(2) 20(1) 
C(7) 8486(3) 6158(5) 5979(2) 21(1) 
C(8) 8531(4) 6746(4) 7652(2) 26(1) 
C(9) 9016(3) 5078(4) 8370(2) 24(1) 
C(10) 6080(3) 4247(5) 1847(2) 27(1) 
C(11) 6102(4) 2142(6) 1594(3) 43(1) 
C(12) 5832(4) 5532(6) 973(2) 42(1) 
________________________________________________________________________________ 
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Table 10- Bond lengths [Å] and angles [°] for 166 
_____________________________________________________  
Br(1)-C(1)  1.929(2) 
Cl(1)-C(9)  1.771(3) 
Cl(2)-C(9)  1.773(3) 
Cl(3)-C(9)  1.767(3) 
O(1)-N(1)  1.436(3) 
O(1)-C(1)  1.463(3) 
O(2)-C(10)  1.425(3) 
O(2)-C(3)  1.425(3) 
O(3)-C(2)  1.415(3) 
O(3)-C(10)  1.437(3) 
O(4)-C(7)  1.198(3) 
O(5)-C(7)  1.358(3) 
O(5)-C(8)  1.434(3) 
N(1)-C(7)  1.360(3) 
N(1)-C(4)  1.480(3) 
C(1)-C(6)  1.493(4) 
C(1)-C(2)  1.525(4) 
C(2)-C(3)  1.544(4) 
C(2)-H(2A)  1.0000 
C(3)-C(4)  1.526(5) 
C(3)-H(3A)  1.0000 
C(4)-C(5)  1.503(5) 
C(4)-H(4A)  1.0000 
C(5)-C(6)  1.322(4) 
C(5)-H(5A)  0.9500 
C(6)-H(6A)  0.9500 
C(8)-C(9)  1.528(4) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(10)-C(12)  1.488(4) 
C(10)-C(11)  1.511(5) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
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C(11)-H(11C)  0.9800 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
 
N(1)-O(1)-C(1) 108.60(16) 
C(10)-O(2)-C(3) 107.3(2) 
C(2)-O(3)-C(10) 107.6(2) 
C(7)-O(5)-C(8) 115.1(2) 
C(7)-N(1)-O(1) 116.19(19) 
C(7)-N(1)-C(4) 120.2(2) 
O(1)-N(1)-C(4) 113.14(18) 
O(1)-C(1)-C(6) 110.1(2) 
O(1)-C(1)-C(2) 105.4(2) 
C(6)-C(1)-C(2) 112.22(19) 
O(1)-C(1)-Br(1) 103.46(13) 
C(6)-C(1)-Br(1) 113.6(2) 
C(2)-C(1)-Br(1) 111.3(2) 
O(3)-C(2)-C(1) 110.9(2) 
O(3)-C(2)-C(3) 105.1(2) 
C(1)-C(2)-C(3) 106.8(2) 
O(3)-C(2)-H(2A) 111.3 
C(1)-C(2)-H(2A) 111.3 
C(3)-C(2)-H(2A) 111.3 
O(2)-C(3)-C(4) 109.4(2) 
O(2)-C(3)-C(2) 104.4(2) 
C(4)-C(3)-C(2) 109.1(2) 
O(2)-C(3)-H(3A) 111.2 
C(4)-C(3)-H(3A) 111.2 
C(2)-C(3)-H(3A) 111.2 
N(1)-C(4)-C(5) 108.3(2) 
N(1)-C(4)-C(3) 103.3(3) 
C(5)-C(4)-C(3) 110.3(2) 
N(1)-C(4)-H(4A) 111.5 
C(5)-C(4)-H(4A) 111.5 
C(3)-C(4)-H(4A) 111.5 
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C(6)-C(5)-C(4) 113.2(3) 
C(6)-C(5)-H(5A) 123.4 
C(4)-C(5)-H(5A) 123.4 
C(5)-C(6)-C(1) 112.4(3) 
C(5)-C(6)-H(6A) 123.8 
C(1)-C(6)-H(6A) 123.8 
O(4)-C(7)-O(5) 125.5(2) 
O(4)-C(7)-N(1) 122.7(2) 
O(5)-C(7)-N(1) 111.5(2) 
O(5)-C(8)-C(9) 111.2(2) 
O(5)-C(8)-H(8A) 109.4 
C(9)-C(8)-H(8A) 109.4 
O(5)-C(8)-H(8B) 109.4 
C(9)-C(8)-H(8B) 109.4 
H(8A)-C(8)-H(8B) 108.0 
C(8)-C(9)-Cl(3) 112.45(19) 
C(8)-C(9)-Cl(1) 106.2(2) 
Cl(3)-C(9)-Cl(1) 109.39(16) 
C(8)-C(9)-Cl(2) 111.5(2) 
Cl(3)-C(9)-Cl(2) 107.92(16) 
Cl(1)-C(9)-Cl(2) 109.40(15) 
O(2)-C(10)-O(3) 104.9(2) 
O(2)-C(10)-C(12) 108.6(3) 
O(3)-C(10)-C(12) 108.6(2) 
O(2)-C(10)-C(11) 110.6(3) 
O(3)-C(10)-C(11) 110.1(3) 
C(12)-C(10)-C(11) 113.7(3) 
C(10)-C(11)-H(11A) 109.5 
C(10)-C(11)-H(11B) 109.5 
H(11A)-C(11)-H(11B) 109.5 
C(10)-C(11)-H(11C) 109.5 
H(11A)-C(11)-H(11C) 109.5 
H(11B)-C(11)-H(11C) 109.5 
C(10)-C(12)-H(12A) 109.5 
C(10)-C(12)-H(12B) 109.5 
H(12A)-C(12)-H(12B) 109.5 
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C(10)-C(12)-H(12C) 109.5 
H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
 
 
  
Table 11- Anisotropic displacement parameters  (Å2x 103) for 166. The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br(1) 16(1)  24(1) 26(1)  0(1) 6(1)  2(1) 
Cl(1) 52(1)  44(1) 20(1)  -7(1) -3(1)  -4(1) 
Cl(2) 30(1)  41(1) 29(1)  6(1) 9(1)  -5(1) 
Cl(3) 28(1)  37(1) 31(1)  0(1) 6(1)  7(1) 
O(1) 13(1)  35(1) 16(1)  4(1) 3(1)  -3(1) 
O(2) 22(1)  40(1) 20(1)  -2(1) 9(1)  1(1) 
O(3) 22(1)  35(1) 16(1)  -4(1) 4(1)  3(1) 
O(4) 19(1)  52(2) 28(1)  -3(1) 4(1)  -11(1) 
O(5) 20(1)  28(1) 16(1)  2(1) 3(1)  -3(1) 
N(1) 12(1)  33(2) 18(1)  3(1) 3(1)  -4(1) 
C(1) 15(1)  20(1) 13(1)  0(1) 4(1)  -1(2) 
C(2) 18(1)  20(1) 18(1)  0(1) 5(1)  2(1) 
C(3) 21(1)  26(2) 18(1)  2(1) 7(1)  4(1) 
C(4) 18(1)  34(1) 18(1)  2(2) 6(1)  -1(2) 
C(5) 28(2)  26(2) 16(1)  -1(1) 10(1)  -5(1) 
C(6) 27(2)  19(1) 14(1)  1(1) 7(1)  -1(1) 
C(7) 21(1)  22(1) 20(1)  2(1) 5(1)  0(1) 
C(8) 32(2)  25(1) 18(1)  -3(1) 2(1)  -3(1) 
C(9) 24(1)  29(2) 19(1)  -4(1) 3(1)  -2(1) 
C(10) 25(1)  38(2) 20(1)  -5(1) 8(1)  2(1) 
C(11) 44(2)  48(2) 42(2)  -19(2) 17(2)  2(2) 
C(12) 41(2)  64(3) 23(2)  5(2) 9(1)  3(2) 
______________________________________________________________________________ 
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Table 12- Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x 10 3) 
for 166. 
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2A) 5171 3079 3617 22 
H(3A) 7836 3133 3732 25 
H(4A) 9220 6102 4259 28 
H(5A) 7819 8972 3638 27 
H(6A) 5020 8933 3472 23 
H(8A) 7858 7651 7926 31 
H(8B) 9495 7443 7574 31 
H(11A) 5103 1799 1136 65 
H(11B) 6996 1883 1285 65 
H(11C) 6223 1378 2198 65 
H(12A) 4843 5180 507 63 
H(12B) 5764 6864 1184 63 
H(12C) 6728 5399 651 63 
________________________________________________________________________________ 
Table 13-  Torsion angles [°] for 166. 
________________________________________________________________  
C(1)-O(1)-N(1)-C(7) 146.6(3) 
C(1)-O(1)-N(1)-C(4) 1.5(3) 
N(1)-O(1)-C(1)-C(6) -57.1(3) 
N(1)-O(1)-C(1)-C(2) 64.2(3) 
N(1)-O(1)-C(1)-Br(1) -178.84(16) 
C(10)-O(3)-C(2)-C(1) 132.5(2) 
C(10)-O(3)-C(2)-C(3) 17.4(3) 
O(1)-C(1)-C(2)-O(3) -178.5(2) 
C(6)-C(1)-C(2)-O(3) -58.7(3) 
Br(1)-C(1)-C(2)-O(3) 69.9(3) 
O(1)-C(1)-C(2)-C(3) -64.5(3) 
C(6)-C(1)-C(2)-C(3) 55.3(3) 
Br(1)-C(1)-C(2)-C(3) -176.07(17) 
C(10)-O(2)-C(3)-C(4) -138.1(2) 
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C(10)-O(2)-C(3)-C(2) -21.5(3) 
O(3)-C(2)-C(3)-O(2) 2.4(3) 
C(1)-C(2)-C(3)-O(2) -115.5(2) 
O(3)-C(2)-C(3)-C(4) 119.2(2) 
C(1)-C(2)-C(3)-C(4) 1.4(3) 
C(7)-N(1)-C(4)-C(5) -90.4(3) 
O(1)-N(1)-C(4)-C(5) 53.1(3) 
C(7)-N(1)-C(4)-C(3) 152.6(2) 
O(1)-N(1)-C(4)-C(3) -63.9(3) 
O(2)-C(3)-C(4)-N(1) 173.1(2) 
C(2)-C(3)-C(4)-N(1) 59.4(3) 
O(2)-C(3)-C(4)-C(5) 57.6(3) 
C(2)-C(3)-C(4)-C(5) -56.1(3) 
N(1)-C(4)-C(5)-C(6) -54.5(3) 
C(3)-C(4)-C(5)-C(6) 57.9(3) 
C(4)-C(5)-C(6)-C(1) 0.1(3) 
O(1)-C(1)-C(6)-C(5) 58.0(3) 
C(2)-C(1)-C(6)-C(5) -59.1(3) 
Br(1)-C(1)-C(6)-C(5) 173.49(19) 
C(8)-O(5)-C(7)-O(4) 7.1(5) 
C(8)-O(5)-C(7)-N(1) -178.5(2) 
O(1)-N(1)-C(7)-O(4) -165.7(3) 
C(4)-N(1)-C(7)-O(4) -23.3(5) 
O(1)-N(1)-C(7)-O(5) 19.7(4) 
C(4)-N(1)-C(7)-O(5) 162.1(3) 
C(7)-O(5)-C(8)-C(9) -107.5(3) 
O(5)-C(8)-C(9)-Cl(3) 64.7(3) 
O(5)-C(8)-C(9)-Cl(1) -175.71(18) 
O(5)-C(8)-C(9)-Cl(2) -56.6(3) 
C(3)-O(2)-C(10)-O(3) 32.7(3) 
C(3)-O(2)-C(10)-C(12) 148.6(2) 
C(3)-O(2)-C(10)-C(11) -86.0(3) 
C(2)-O(3)-C(10)-O(2) -31.1(3) 
C(2)-O(3)-C(10)-C(12) -147.0(3) 
C(2)-O(3)-C(10)-C(11) 87.9(3) 
________________________________________________________________  
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7. Selected Spectra 
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